How to Cite
Abstract
This study described the peculiarity of the clinical phenotypes and the pattern of reproductive hormones among women with PCOS in Nigerian populace.
A total of 90 consented volunteers consisting of 45 PCOS and 45 controls were recruited. The diagnosis of PCOS was established using the International PCOS guidelines 2018. Demographic, anthropometric, and clinicopathological data were obtained from each participant. Hormonal assay was done using the electrochemiluminescence (ECL) technology (Roche Diagnostics, Switzerland). Statistical analysis was done using the Statistical Package for the Social Sciences (SPSS) version 25.
Polycystic ovaries (PCO) are the most popular feature of PCOS, observed in more than 90% of PCOS subjects followed by oligomenorrhea (68 %), while hirsutism and acne were found in about 50% of the cases. The study shows 62 % of PCOS subjects had phenotype D, 52 % Phenotype C, 40 % Phenotype B, while 38 % had Phenotype A. Increased levels of Anti-Mullerian hormone (AMH), Testosterone, Prolactin, Luteinizing hormone (LH) and LH: FSH were observed in PCOS with median (95% Confidence interval) of 4.98(3.4-7.1), 32.5(19.75-53.0), 401.6(230.9-623.0), 9.23(5.4-16.6) and 2.03(1.48-3.58), respectively compared to control [1.43(0.8-2.4), 19.0(12.3-29.5), 252.2(196.3-337.0), 6.36(4.0-12.6) and 1.47(0.7-2.4), respectively] (p<0.05). The serum levels of follicle-stimulating hormone (FSH), estradiol, and sex hormone binding globulin (SHBG) were lower in PCOS with values of 5.21(3.6-5.9), 70.45(50.5-145.9) and 44.84(27.3-75.7), respectively compared to controls [6.0(4.4-7.9), 104.0(64.6-216.6) and 74.05(54.0-96.8), respectively] (P<0.05). FSH, LH:FSH, AMH, testosterone, estradiol, SHBG, and prolactin show significant odd ratio with risk analysis in PCOS (p<0.05). There existed a negative correlation between the hormones (Estradiol and AMH) and the PCOS phenotypes (estimated Spearman’s rho were -.310 and -.348, respectively) (p<0.05).
Phenotype D and C characterized by ovulatory dysfunction, polycystic ovary morphology and hyperandrogenism are the two predominant phenotypes of PCOS in our study population. This is accompanied by marked changes in hormonal pattern among PCOS subjects, particularly steroids and follicular hormones. Modulating this phenotype-hormonal interplay may support or improve PCOS management in the study population
References
REFERENCES
1. Conway G, Dewailly D, Diamanti-Kandarakis E, et al. (2014) ESE PCOS Special Interest Group. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol; 171: 1–29. doi: 10.1530/EJE-14-0253.
2. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz B. ( 2016)The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod; 31: 2841–2855. doi: 10.1093/humrep/dew218.
3. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. (1935) American Journal of Obstetrics and Gynecology; 29:181 - 191.
4. Dewailly D, Marla EL, Carmina E, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome (2014) Society, Human Reproduction Update; 20: 334–352. https://doi.org/10.1093/humupd/dmt061.
5. Teede HJ, Misso ML, Costello MF, et al. (2018) Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod; 33:1602-1618. doi: 10.1093/humrep/dey256.
6. Kabel AM. Polycystic Ovarian Syndrome: Insights into Pathogenesis, Diagnosis, Prognosis, Pharmacological and Non-Pharmacological Treatment. (2016) Journal of Pharmacological Reports; 1: 103.
7. Adewuni D, Samuel TA, Iranloye B, Magbagbeola O, Akinloye O (2022). Metabolic Syndrome Associated with Polycystic Ovary Syndrome in Some Nigerian Women. Pan Afri J life Sci; 5: 361-367.
8. Bednarska S, Siejka A. (2017). The pathogenesis and treatment of polycystic ovary syndrome: What’s new? Adv Clin Exp Med; 26: 359–367.
9. Ganie MA, Vasudevan V, Wani IA, Baba MS, Arif T, Rashid A (2019). Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. Indian J Med Res; 150: 333–344.
10. Lewandowski KC, Cajdler-Luba A, Salata I, Bienkiewicz M, Lewinski A (2011). The Utility of the gonadotropin releasing hormone (GnRH) test in the diagnosis of Polycystic Ovary Syndrome (PCOS). Endokrynol Pol.; 62:120-128
11. Garg D, Berga SL. (2020) Neuroendocrine mechanisms of reproduction. Handb. Clin. Neurol; 3–23. doi:10.1016/b978-0-444-64239-4.00001-1.
12. Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S. (2019) Comparison of the different PCOS phenotypes based on clinical metabolic, and hormonal profile, and their response to clomiphene. Indian Journal of Endocrinology and Metabolism,; 23: 326-31.
13. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. (2016) Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil. Steril,; 106: 6-15.
14. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. (2015) Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev.; 36: 487- 525.
15. McCartney CR, Eagleson CA, Marshall JC. (2002) Regulation of gonadotropin secretion: implications for polycystic ovary syndrome. Semin Reprod Med,; 20: 317-326.
16. Morshed S, Hurjahan B, Nazma A, et al. (2021) Luteinizing Hormone to Follicle-Stimulating Hormone Ratio Significantly Correlates with Androgen Level and Manifestations Are More Frequent with Hyperandrogenemia in Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab; 11: 14-21.
17. Parahuleva N, Pehlivanov B, Orbecova M, Deneva T, Uchikova E. (2013) Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age]. Akush Ginekol (Sofiia).; 52:16-23. PMID: 24294740.
18. Desforges-Bullet V, Gallo C, Lefebvre C, Pigny P, Dewailly D, Catteau-Jonard S. (2010) Increased anti-Müllerian hormone and decreased FSH levels in follicular fluid obtained in women with polycystic ovaries at the time of follicle puncture for in vitro fertilization. Fertil Steril; 94: 198-204.
19. Pellatt L, Hanna L, Brincat M, et al. (2007) Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab.; 92: 240-5. doi: 10.1210/jc.2006-1582.
20. Hobeika E, Armouti M, Fierro MA. (2020) Regulation of Insulin-Like Growth Factor 2 by Oocyte-Secreted Factors in Primary Human Granulosa Cells. J Clin Endocrinol Metab;105: 327 - 335. DOI: 10.1210/clinem/dgz057.
21. Goodarzi MO, Carmina E, Azziz R. (2015) DHEA, DHEAS and PCOS. J Steroid Biochem Mol Biol,; 145: 213-25.
22. Qu X, Donnelly R. (2020) Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome. Int J Mol Sci.; 21:8191. doi: 10.3390/ijms21218191.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Nigerian Journal of Physiological Sciences